AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock

Rhea-AI Summary

AIkido Pharma Inc. (Nasdaq: AIKI) has concluded its public offering of 46,875,000 shares at $1.60 per share, generating gross proceeds of $75 million. The offering includes an underwriter's option for an additional 7,031,250 shares. The funds are earmarked for working capital and general corporate purposes. The offering was registered under Form S-3 and is linked to their ongoing development of anti-cancer therapeutics and antiviral platforms.

Positive

• Gross proceeds of $75 million intended for working capital and corporate purposes.
• Continued development of proprietary anti-cancer therapeutics and broad-spectrum antiviral platforms.

Negative

• Potential dilution of existing shares due to the public offering.

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the closing of its previously announced underwritten public offering of 46,875,000 shares of its common stock at a price to the public of $1.60 per share. As previously announced, the Company has granted to the underwriter a 30-day option to purchase up to 7,031,250 additional shares of common stock at the public offering price, less underwriting discounts and commissions.

H.C. Wainwright & Co. acted as the sole book-running manager for the offering.

The gross proceeds to the Company from the offering are $75 million, before deducting underwriting discounts and commissions and other offering expenses. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. 

The offering was conducted pursuant to the registration statement on Form S-3 (File No. 333-238172), as amended, previously filed with and subsequently declared effective by the Securities and Exchange Commission ("SEC") on June 18, 2020. The offering was made only by means of a prospectus supplement and accompanying base prospectus. A final prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC and are available for free on the SEC's website located at http://www.sec.gov. and may also be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (646) 975-6996, or by email to placements@hcwco.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying base prospectus forming a part of the effective registration statement.

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:      

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.:   

Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock-301231770.html

SOURCE AIkido Pharma Inc.

FAQ

What is the purpose of AIkido Pharma's public offering on Feb 19, 2021?

The public offering aims to raise funds for working capital and general corporate purposes.

How many shares did AIkido Pharma issue in the recent offering?

AIkido Pharma issued 46,875,000 shares in the recent public offering.

What is the offering price per share for AIkido Pharma's recent public offering?

The offering price per share was $1.60.

What are the gross proceeds from AIkido Pharma's share offering?

The gross proceeds from the offering amount to $75 million.

Is there an option for additional shares in AIkido Pharma's offering?

Yes, the underwriter has a 30-day option to purchase up to 7,031,250 additional shares.